Diseases have long been defined by their symptoms, and therefore patients have typically been treated when they are symptomatic. New tools and innovations will enable a transition from Precision Medicine where the molecular etiology is determined after symptoms appear, to Precision Health in which the molecular etiology of diseases can be anticipated and symptoms averted. However, is it ethical to treat “asymptomatic disease” and at what cost to the healthcare system? What level of risk will be tolerated for interventions that are developed for treating “pre-diseased” patients? Since many of these assays will predict likelihood of disease and not absolute progression to disease, what level of certainty is needed to intervene at all?

Christopher H. Contag, PhD, is a John A. Hannah Distinguished Professor of Biomedical Engineering and Microbiology & Molecular Genetics, Chair of the Department of Biomedical Engineering, and Director of the Institute for Quantitative Health Science and Engineering at Michigan State University.

12 - 1 pm lecture and Q&A
Please join us in person or live on the web!

In person: C102 Patenge Rm, East Fee Hall

Online: msubioethics.clickwebinar.com/brownbag

This lecture is free and open to the public. You are welcome to bring your lunch. Beverages and light snacks will be provided. All lectures are recorded and posted online in our webinar archive.